Cargando…

The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study

BACKGROUND: Worldwide, the use of prostate specific antigen (PSA) testing as a screen for prostate cancer is contentious. Whilst there is no National UK Screening programme, many men undergo opportunistic screening. This study investigates UK urologist's usage of PSA and the awareness surroundi...

Descripción completa

Detalles Bibliográficos
Autores principales: Burden, Helena P, Davis, Chris R, Tate, Sophie, Persad, Raj, Holmes, Chris H, Whittington, Kate
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606676/
https://www.ncbi.nlm.nih.gov/pubmed/19021912
http://dx.doi.org/10.1186/1471-2490-8-17
_version_ 1782162982757728256
author Burden, Helena P
Davis, Chris R
Tate, Sophie
Persad, Raj
Holmes, Chris H
Whittington, Kate
author_facet Burden, Helena P
Davis, Chris R
Tate, Sophie
Persad, Raj
Holmes, Chris H
Whittington, Kate
author_sort Burden, Helena P
collection PubMed
description BACKGROUND: Worldwide, the use of prostate specific antigen (PSA) testing as a screen for prostate cancer is contentious. Whilst there is no National UK Screening programme, many men undergo opportunistic screening. This study investigates UK urologist's usage of PSA and the awareness surrounding the Department of Health (DoH) PSA guidelines. METHODS: Urologists were sent a questionnaire regarding PSA cut-off values. RESULTS: Of the 733 urologists eligible to participate in this study 346 returned completed questionnaires giving a response rate of 47%. The most commonly generally used age-related PSA cut-off values (36% of respondents) are – 3.5 ng/ml for 50 – 59 year olds, 4.5 ng/ml for 60 – 69 year olds and 6.5 ng/ml for over 70 year olds. Two-thirds (58%, 200/346) of respondents were aware of the DoH PSA guidelines but only 20% (n = 69/346) follow these guidelines. The majority of respondents (68%, n = 234/346) used higher PSA cut-offs than recommended by the DoH. The level of compliance showed marked regional variation with a range from 7% to 44% (median 19%). In addition, it was apparent that lower PSA cut-off values were used in private practice as opposed to the National Health Service. CONCLUSION: A nationwide lack of agreement on PSA cut-off values may generate a variable standard of care both regionally and in NHS versus private practice. Generally, higher PSA cut-off values are being used than recommended by the DoH guidance.
format Text
id pubmed-2606676
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26066762008-12-23 The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study Burden, Helena P Davis, Chris R Tate, Sophie Persad, Raj Holmes, Chris H Whittington, Kate BMC Urol Research Article BACKGROUND: Worldwide, the use of prostate specific antigen (PSA) testing as a screen for prostate cancer is contentious. Whilst there is no National UK Screening programme, many men undergo opportunistic screening. This study investigates UK urologist's usage of PSA and the awareness surrounding the Department of Health (DoH) PSA guidelines. METHODS: Urologists were sent a questionnaire regarding PSA cut-off values. RESULTS: Of the 733 urologists eligible to participate in this study 346 returned completed questionnaires giving a response rate of 47%. The most commonly generally used age-related PSA cut-off values (36% of respondents) are – 3.5 ng/ml for 50 – 59 year olds, 4.5 ng/ml for 60 – 69 year olds and 6.5 ng/ml for over 70 year olds. Two-thirds (58%, 200/346) of respondents were aware of the DoH PSA guidelines but only 20% (n = 69/346) follow these guidelines. The majority of respondents (68%, n = 234/346) used higher PSA cut-offs than recommended by the DoH. The level of compliance showed marked regional variation with a range from 7% to 44% (median 19%). In addition, it was apparent that lower PSA cut-off values were used in private practice as opposed to the National Health Service. CONCLUSION: A nationwide lack of agreement on PSA cut-off values may generate a variable standard of care both regionally and in NHS versus private practice. Generally, higher PSA cut-off values are being used than recommended by the DoH guidance. BioMed Central 2008-11-20 /pmc/articles/PMC2606676/ /pubmed/19021912 http://dx.doi.org/10.1186/1471-2490-8-17 Text en Copyright © 2008 Burden et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Burden, Helena P
Davis, Chris R
Tate, Sophie
Persad, Raj
Holmes, Chris H
Whittington, Kate
The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study
title The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study
title_full The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study
title_fullStr The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study
title_full_unstemmed The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study
title_short The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study
title_sort trends in prostate specific antigen usage amongst united kingdom urologists – a questionnaire based study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606676/
https://www.ncbi.nlm.nih.gov/pubmed/19021912
http://dx.doi.org/10.1186/1471-2490-8-17
work_keys_str_mv AT burdenhelenap thetrendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT davischrisr thetrendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT tatesophie thetrendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT persadraj thetrendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT holmeschrish thetrendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT whittingtonkate thetrendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT burdenhelenap trendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT davischrisr trendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT tatesophie trendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT persadraj trendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT holmeschrish trendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy
AT whittingtonkate trendsinprostatespecificantigenusageamongstunitedkingdomurologistsaquestionnairebasedstudy